东方证券股份有限公司 关于苏州富士莱医药股份有限公司 2024 年持续督导培训工作报告 根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》等相关法律法规及规范性文件的规定，东方证券 股份有限公司（以下简称"东方证券"）作为苏州富士莱医药股份有限公司（以 下简称"富士莱、公司"）首次公开发行股票并在创业板上市的持续督导机构， 于 2025 年 4 月 14 日对富士莱的实际控制人、主要董事、监事、高级管理人员、 中层以上管理人员等相关人员进行了培训，现将本次培训情况汇报如下： 一、本次持续督导培训的基本情况 实施本次持续督导培训前，东方证券编制了培训讲义，并提供给富士莱参与 培训的相关人员，要求其提前了解培训相关内容。 东方证券围绕上市公司信息披露、股份增减持、募集资金使用等角度，对相 关人员展开培训。公司相关培训人员通过现场的形式参加了培训。 三、培训效果 本次培训促使富士莱董事、监事、高级管理、中层以上管理人员等培训对象 加深了对中国证券监督管理委员会和深圳证券交易所相关法律、法规、业务规则 的了解和认识，促使培训对象进一步理解上市公司工作规范和信息披露要求 ...

募集资金年度存放与使用情况鉴证报告 苏州富士莱医药股份有限公司 容诚专字[2025]230Z0205 号 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | 1 | 募集资金年度存放与使用情况鉴证报告 | | 1-3 | | 2 | 募集资金年度存放与使用情况专项报告 | | 1-5 | 容诚会计师事务所（特殊普通合伙） 募集资金年度存放与使用情况鉴证报告 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 容诚专字[2025]230Z0205 号 苏州富士莱医药股份有限公司全体股东： 我们审核了后附的苏州富士莱医药股份有限公司（以下简称富士莱公司）董 事会编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、 对报告使用者和使用目的的限定 本鉴证报告仅 ...

东方证券股份有限公司 关于苏州富士莱医药股份有限公司 2024 年度证券与衍生品投资情况的核查意见 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"）作为苏州 富士莱医药股份有限公司（以下简称"富士莱"或"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2号 ——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等法律法规的有关规定，对富士莱2024年度证券与衍生品投资 情况进行了核查，具体情况如下： 一、证券与衍生品投资审议情况 1、以套期保值为目的的衍生品投资 2024 年 3 月 12 日，公司召开了第四届董事会第十二次会议、第四届监事会 第十一次会议以及 2024 年 3 月 29 日召开 2024 年第二次临时股东大会，审议通 过了《关于开展外汇衍生品交易业务的议案》，同意公司开展外汇衍生品交易， 任一时点交易金额累计不超过 1 亿美金，期限自 2024 年第二次临时股东大会审 议通过之日起 12 个月，上述额度在期限内可循环滚动使用。 2 ...

2024 年度营业收入扣除情况的 专项审核报告 苏州富士莱医药股份有限公司 容诚专字[2025]230Z0204 号 容诚会计师事务所(特殊普通合伙) 中国·北京 | | | | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | 1 | 营业收入扣除情况的专项审核报告 | | 1-2 | | 2 | 营业收入扣除情况表 | | 1 | 我们认为，后附的富士莱公司 2024 年度营业收入扣除情况表在所有重大方面 按照《深圳证券交易所创业板股票上市规则》和《深圳证券交易所创业板上市公 司自律监管指南第 1 号——业务办理》的规定编制，公允反映了富士莱公司营业 收入扣除情况。 为了更好地理解富士莱公司营业收入扣除情况，后附营业收入扣除情况表应 1 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 关 ...

东方证券股份有限公司 关于苏州富士莱医药股份有限公司 2024 年度持续督导跟踪报告 | 保荐机构名称：东方证券股份有限公司 | 被保荐公司简称：富士莱 | | --- | --- | | 保荐代表人姓名：王宽 | 联系电话：021-23153888 | | 保荐代表人姓名：张仲 | 联系电话：021-23153888 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易制 | | | 度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 保荐机构每月查询公司募集资金专户资 | | | 金变动情况和大额资金支取使用情况 | | （2 ...

东方证券股份有限公司关于 苏州富士莱医药股份有限公司 截至 2023 年 12 月 31 日，公司已累计使用募集资金 59,120.91 万元。2024 年度，公 司使用募集资金 3,922.94 万元。截至 2024 年 12 月 31 日，公司已累计使用募集资金 63,043.85 万元，其中：直接投入募集资金项目 53,143.85 万元，超募资金永久补充流动 资金 9,900.00 万元。 截至 2024 年 12 月 31 日，公司募集资金余额为 36,376.26 万元，其中：使用闲置募 集资金购买保本型理财产品未到期本金余额为 32,700.00 万元，募集资金专用银行账户 余额为 3,676.26 万元。具体情况如下： 8 单位：万元 | 项目 | | 金额 | | | | --- | --- | --- | --- | --- | | 募集资金总额 | | | 110,703.60 | | | 减：支付部分发行费用 | | | | 10,770.87 | | 减：募集资金置换前期自筹资金投入 | | | | 22,757.72 | | 减：累计使用募集资金 | | | | 40,489.94 ...

Financial Performance - The company reported a significant decline in net profit during the fiscal year, with specific reasons and measures for improving profitability detailed in the management discussion section [5]. - The company's operating revenue for 2024 was ¥429,468,011.82, a decrease of 12.23% compared to ¥489,292,586.96 in 2023 [16]. - The net profit attributable to shareholders for 2024 was ¥16,406,148.23, down 85.38% from ¥112,181,787.31 in 2023 [16]. - The cash flow from operating activities for 2024 was ¥47,068,013.45, a decline of 50.33% from ¥94,768,588.39 in 2023 [16]. - The basic earnings per share for 2024 was ¥0.18, representing an 85.25% decrease from ¥1.22 in 2023 [16]. - The total assets at the end of 2024 were ¥2,087,754,088.26, a decrease of 1.34% from ¥2,116,079,866.90 at the end of 2023 [16]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a net loss of ¥8,924,873.45 in 2024 compared to a profit of ¥89,606,898.67 in 2023, marking a 109.96% decrease [16]. - In 2024, the company's total revenue was CNY 42,946.80 million, a decrease of 12.23% year-on-year, with main business revenue at CNY 42,600.68 million, down 11.82% [50]. - The company's net profit attributable to shareholders was CNY 1,640.61 million, a significant decline of 85.38% year-on-year, with a net profit excluding non-operating gains and losses at -CNY 892.49 million, down 109.96% [56]. Dividend Distribution - A cash dividend of 0.91 yuan (including tax) per 10 shares will be distributed to shareholders, based on a total share capital of 90,790,000 shares after excluding repurchased shares [5]. - The company distributed a cash dividend of 6 RMB per 10 shares, totaling 54,996,000 RMB, based on a total share capital of 91,660,000 shares [145]. - The company announced a cash dividend of 0.91 RMB per 10 shares, totaling 8,261,890 RMB (including tax), which represents 100% of the distributable profit [146]. - The total number of shares for the dividend distribution is based on 90,790,000 shares after excluding 880,000 shares repurchased [146]. Market and Industry Outlook - The global pharmaceutical market reached approximately $1.61 trillion in 2023, with an expected compound annual growth rate of 6.85% until 2028 [25]. - The global raw material and intermediate market size was estimated at $180 billion to $200 billion in 2023, with a projected growth rate of 6% to 8% over the next few years [26]. - The Chinese pharmaceutical industry saw a revenue of ¥29,762.7 billion in 2024, remaining flat year-on-year, while profits decreased by 0.9% to ¥4,050.9 billion [27]. - The chemical raw material sector experienced a revenue growth of 0.3% and a profit increase of 6.9% in 2024, contrasting with declines in other sub-sectors [27]. - The global market demand for APIs remains strong, driven by China's technological accumulation and cost advantages, although the average export price has declined due to increasing competition [30]. Research and Development - The company holds 49 patents, including 48 invention patents, and has a robust R&D platform to support sustainable development and reduce reliance on single products [37]. - The company invested CNY 4,062.02 million in R&D in 2024, accounting for 9.46% of total revenue, an increase of 1.14 percentage points year-on-year [58]. - The company is focusing on the registration and certification of high-end lipoic acid raw materials in the European and American regulatory markets to enhance its international market share [45]. - The company aims to expand its international market share through patent applications and regulatory certifications for core products [108]. - The company will continue to increase R&D investment, particularly in the development of new product lines for pharmaceutical intermediates and specialty raw materials [108]. Environmental Compliance - The company has achieved ISO 14001:2015 certification for its environmental management system, reflecting its commitment to environmental protection and sustainable practices [111]. - The company received environmental impact assessment approvals for multiple projects, including a 1000 tons/year project for L-carnitine and derivatives, with approvals dating back to November 2010 [154]. - The company has a valid pollutant discharge permit effective until September 10, 2029, allowing emissions of volatile organic compounds, particulate matter, sulfur dioxide, nitrogen oxides, and other pollutants [155]. - The company has implemented multiple emission outlets, with a total of 3 for ammonia and 2 for benzene [156]. - The company has established a comprehensive environmental management strategy that includes waste gas, wastewater, and noise treatment facilities to meet operational needs [161]. Corporate Governance - The company operates independently from its controlling shareholders in terms of assets, personnel, finance, organization, and business, ensuring a complete and independent business system [118]. - The company has established a clear governance structure with independent boards and committees, ensuring no institutional overlap with controlling shareholders [119]. - The company has a structured remuneration decision-making process based on individual roles and contributions [132]. - The company has established a comprehensive internal audit plan for 2024, reflecting its commitment to governance and oversight [139]. - The company has implemented a comprehensive employee social insurance management system to safeguard labor rights [169]. Strategic Partnerships and Market Expansion - The company aims to expand its market share by actively exploring emerging domestic and international markets, leveraging its competitive advantages in three major product series [45]. - The company is collaborating with large pharmaceutical formulation companies to develop CMO/CDMO business, aiming for sustainable growth in high-end specialty raw materials [45]. - The company is actively developing strategic partnerships with customers and suppliers to enhance cooperation and mutual benefits [169]. - The company plans to strengthen its core product market position by increasing shipment volumes and market share while optimizing production processes to reduce costs [108]. - The company is committed to building a sustainable product portfolio of high-end specialty raw materials and patented raw materials through CMO/CDMO business collaborations [108].

Financial Performance - The company's revenue for Q1 2025 reached ¥113,084,277.89, representing a 17.44% increase compared to ¥96,291,253.79 in the same period last year[5] - Net profit attributable to shareholders surged to ¥23,936,842.19, a remarkable increase of 313.65% from ¥5,786,807.10 year-on-year[5] - The basic earnings per share rose to ¥0.2636, reflecting a 317.75% increase compared to ¥0.0631 in the previous year[5] - Total operating revenue for the current period reached ¥113,084,277.89, an increase of 17.5% compared to ¥96,291,253.79 in the previous period[23] - Net profit for the current period was ¥23,936,842.19, a significant increase of 314.5% compared to ¥5,786,807.10 in the previous period[24] - Operating profit rose to ¥27,898,843.72, compared to ¥6,257,225.69 in the previous period, reflecting a growth of 345.5%[24] - The basic and diluted earnings per share improved to ¥0.2636, compared to ¥0.0631 in the previous period, marking a growth of 317.5%[25] Cash Flow and Investments - The net cash flow from operating activities was negative at -¥24,149,397.84, a decline of 750.71% from -¥2,838,727.69 in the same period last year[13] - The cash flow from investing activities improved by 26.58%, reaching ¥102,669,239.22 compared to ¥81,112,270.67 in the previous year[13] - Investment activities generated a net cash flow of 102,669,239.22, an increase of 26.5% compared to the previous period's 81,112,270.67[27] - Cash inflow from investment activities totaled 868,852,833.51, while cash outflow was 766,183,594.29, resulting in a positive cash flow from investments[27] - The net increase in cash and cash equivalents for the period was 77,751,424.08, slightly down from 78,347,272.05 in the previous period[27] - The ending balance of cash and cash equivalents was 302,478,193.29, a decrease from 428,082,370.02 in the prior period[27] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets was 22,523,468.80, up from 21,117,677.71[27] - Cash paid for investments was 743,660,125.49, down from 825,044,213.45 in the previous period[27] - Cash outflow from financing activities totaled 847,299.84, compared to 430,627.86 in the prior period, indicating an increase in financing costs[27] - The impact of exchange rate changes on cash and cash equivalents was a positive 78,882.54, down from 504,356.93[27] Assets and Liabilities - Total assets increased by 1.19% to ¥2,112,564,060.31 from ¥2,087,754,088.26 at the end of the previous year[5] - The total liabilities increased to ¥202,275,167.22 from ¥200,840,818.36, indicating a growth of 0.7%[22] - Total equity attributable to shareholders reached ¥1,910,288,893.09, up from ¥1,886,913,269.90, reflecting an increase of 1.2%[22] - The total liabilities include accounts payable of ¥76,637,124.39, which increased from ¥69,926,185.32, showing a rise of about 9.7%[21] - The company reported a total of 1,627,457,229.27 in current assets, slightly up from 1,611,600,814.83, marking an increase of approximately 1.4%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 101,851[15] - The largest shareholder, Suzhou Fushilai Technology Service, holds 60.22% of the shares, totaling 55,200,000 shares[15] - The number of shares held by the top 10 shareholders includes a repurchase account holding 880,000 shares, accounting for 0.96% of the total share capital[15] - The company has no significant changes in the number of preferred shareholders or major shareholders participating in margin trading[16] Other Information - The company reported a significant increase in investment income and fair value changes, contributing to the net profit growth[11] - The company reported a 1943.26% increase in income tax expenses, correlating with the substantial rise in net profit[11] - Research and development expenses decreased to ¥8,922,646.28 from ¥11,313,681.30, a reduction of 21.1%[24] - The company did not undergo an audit for the first quarter report[28] - The new accounting standards will be implemented starting in 2025, affecting the financial statements[28] - There are no other important matters reported during the conference call[18]

苏州富士莱医药股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人金春卿作为苏州富士莱医药股份有限公司（以下简称"公司"）的独立董 事，在 2024 年度的工作中，本人严格按照《公司法》《上市公司独立董事管理 办法》等法律法规和《公司章程》《独立董事工作制度》的规定，忠实履行职责， 通过出席相关会议及多渠道了解公司经营情况，积极发挥了独立董事的作用，维 护了公司整体利益和全体股东尤其是中小股东的合法权益。现将 2024 年度履职 情况报告如下： 一、独立董事的基本情况 经 2022 年 9 月 9 日召开 2022 年第二次临时股东大会审议通过，本人被选举 为公司第四届董事会独立董事，本人个人工作履历、专业背景以及兼职情况如下： 1965 年 3 月出生，中国国籍，无境外永久居留权，硕士研究生学历。1989 年 7 月至 1999 年 2 月历任苏州大学王健法学院助教、讲师、副教授；现任中国 国际经济贸易仲裁委员会仲裁员、上海国际经济贸易仲裁委员会仲裁员、南京大 学法学院校外导师、上海财经大学法学院研究生导师、苏州西交利物浦大学校外 导师以及最高人民检察院涉外民商法和知识产权外部专家。19 ...

苏州富士莱医药股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人 CAO CHUANXING（曹传兴）作为苏州富士莱医药股份有限公司（以 下简称"公司"）的独立董事，在 2024 年度的工作中，本人严格按照《公司法》 《上市公司独立董事管理办法》等法律法规和《公司章程》《独立董事工作制度》 的规定，忠实履行职责，通过出席相关会议及多渠道了解公司经营情况，积极发 挥了独立董事的作用，维护了公司整体利益和全体股东尤其是中小股东的合法权 益。现将 2024 年度履职情况报告如下： 一、独立董事的基本情况 经 2024 年 3 月 29 日召开 2024 年第二次临时股东大会审议通过，本人被选 举为公司第四届董事会独立董事，本人个人工作履历、专业背景以及兼职情况如 下： 1963 年 11 月出生，美国国籍，拥有中国永久居留权，研究生学历，现已退 休。1988 年 9 月至 1995 年 7 月先后任东南大学助教、讲师、副教授；1999 年 12 月至 2003 年 12 月，任美国 ADS 公司高级工程师；2004 年 7 月至 2021 年 12 月 任江苏达诺尔科技股份有限公司总经理、董事 ...